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1. Introduction  
The goal of tissue engineering is to synthesise substitutes that mimic the natural 
environment to help guide the growth of new functional biological tissue in vitro or in vivo. 
Tissue engineering relies heavily on the use of porous 3D scaffolds to provide a supportive 
environment for the regeneration of tissues and organs, acting primarily as a template for de 
novo tissue formation. However, new advances in fabrication technologies and composite 
materials are facilitating the rapid development of many novel composites that are 
beginning to play a more active role in directing the regenerative process. It has been long 
recognised that the combination of two or more characteristically-distinct materials can 
often yield composite materials that possess many of the constituent materials mechanical 
and biological advantages with few of their disadvantages. When applied to regenerative 
medicine, these new composite materials are beginning to show real potential as bioactive, 
biodegradable substitute materials, capable of facilitating rapid orthopaedic tissue 
regeneration, while degrading in parallel with the advancing tissue repair process. These 
idealised tissue regenerative aids could finally offer clinicians the potential to completely 
regenerate damaged orthopaedic tissue, leaving no evidence that the tissue was ever 
damaged in the first instance. 
At a simplistic level, biological tissues consist of cells, signalling mechanisms and 
extracellular matrix (ECM). Tissue engineering technologies are based on this biological 
triad and consist of (i) the scaffold that holds the cells together to create the tissue’s physical 
form, (ii) the cells that create the tissue, and (iii) the biological signalling mechanisms (such 
as growth factors or bioreactors) that direct the cells to express the desired tissue phenotype 
(Figure 1). In native tissues, cells are held within an ECM which guides development and 
directs regeneration of the tissue. The ECM serves to organise cells in space and provides 
them with environmental signals to direct cellular behaviour. Consequently, the ECM is 
responsible for two of the three components in this tissue engineering triad, highlighting the 
critical role that this extracellular environment plays on tissue formation. What is becoming 
increasingly evident is that the combination of biomaterials into novel composite scaffolds 
can result in an engineered biomimicry of this extracellular environment that provide all the 
environmental cues to promote rapid development of de novo tissue. Consequently, these 
composites can be designed to act not only as carriers and supporting structures for the 
associated cells but to play a more active role in the initiation and development of the repair 
tissue.  
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Fig. 1. The tissue engineering triad; factors that need to be considered when designing a 
suitable structure for tissue engineering applications 
2. Scaffold requirements 
Traditionally, scaffolds designed for tissue engineering attempted to meet a small number of 
common requirements that would allow them to be used safely for the in vitro production 
of engineered tissue or alternatively for in vivo implantation as regenerative aids. These 
included (i) providing an environment conducive to the facilitation of desirable cell-matrix 
interactions (e.g. cellular infiltration, attachment, proliferation and differentiation), (ii) 
support nutrient and waste product transport and encourage the movement of biochemical 
signals throughout the structure/matrix, facilitating long-term cellular survival and 
proliferation, (iii) biodegrade at an appropriate rate in parallel with the body’s own natural 
healing process (i.e. supporting the healing phase while in tandem ensuring that the scaffold 
does not act as a barrier to the regenerative process, and (iv) to be bioinert and provoke a 
minimal inflammatory or immunological response as a result of its implantation or 
population with cells.  
When designing or evaluating a scaffold for applications in tissue regeneration, there are a 
number of scaffold architectural, compositional and physical characteristics that have a 
deterministic influence on these four overlying tissue engineering scaffold requirements; 
1. Biocompatibility 
The word biocompatibility was mentioned for the first time in peer-review journals and 
meetings in 1970 by RJ Hegyeli and CA Homsy (Homsy et al., 1970). The definition of 
biocompatibility is “the ability of a material to perform with an appropriate host 
response in a specific application” and is a critical criterion for scaffold design. Not only 
must the scaffold material itself be biocompatible, but so too must its degradation 
products in vivo. It must not elicit toxic or injurious responses within biological systems 
once implanted or at any point throughout the degradation of the material in vivo. This 
characteristic alone rules out many synthetic or man-made materials as suitable 
components of tissue engineering matrices. 
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2. Biodegradability 
Biodegradability refers to the ability of the physiological environment to breakdown or 
degrade an implanted material. Biodegradation is a critical characteristic of materials 
that are designed to regenerate tissue, as opposed to acting simply as inert substitutes 
for the native tissue. The overall goal of cutting edge regenerative tissue engineering 
therapies is to act as “smart” biomaterials by supporting the initial healing processes 
while also beginning to degrade in parallel with the advancing production of newly 
formed tissue matrix, ideally with no evidence of implantation once sufficient tissue 
regeneration has occurred, negating the need for subsequent clinical interventions to 
remove the implant from the body. 
3. Bulk Mechanical Properties 
The scaffold should provide an environment that is capable of surviving the 
implantation process and surgical manipulation required as part of the clinical 
procedure. It is widely believed that these materials must possess adequate mechanical 
integrity to survive the normal physiological loading environment at the site of 
implantation but this is currently an area of contention within the field. Traditional 
tissue engineering scaffolds prioritise a mechanically-competent scaffold, capable of 
supporting load bearing immediately upon implantation. Unfortunately, the 
characteristics of host tissue-like mechanical strength and the levels of porosity, 
permeability and pore interconnectivity, necessary for long-term scaffold in vitro and in 
vivo viability, are incompatible from a biomaterials perspective. Consequently current 
scaffolds are utilising cutting-edge advancements in composite biomaterials technology 
in an attempt to balance provision of bulk mechanical properties suitable for 
implantation and cellular support while retaining a material porosity high enough to 
encourage cell infiltration via diffusion throughout the scaffold. 
4. Substrate Stiffness 
Substrate mechanical properties of tissue engineering scaffolds plays a critical role in 
controlling and regulating a number of  factors involved in  directing cellular activity 
(Engler et al., 2006). Recent unpublished work from our laboratory has demonstrated 
that collagen-based scaffolds with a bulk stiffness of approximately 4 kPa exhibit 
increased cell attachment, proliferation and migration compared to less stiff scaffolds. 
Interestingly, recent studies have investigated the bulk and localised mechanical 
properties of highly porous scaffolds (Harley et al., 2007) and shown that the nature of 
high porosity structures means that their bulk mechanical properties are dramatically 
different to the mechanical properties of the individual struts within the open foam 
network. As a result, the substrate stiffness that a cell ‘feels’ while attached to one or 
multiple struts within the porous scaffold can be significantly higher than that 
predicted by bulk assessment of the material. Based on their study, it was estimated 
that the substrate stiffness experienced by a cell attached to a pore within a highly 
porous scaffold exhibiting a bulk stiffness of approximately 4 kPa would be of the order 
of approximately 50 to 100 MPa. Therefore, the effect of local substrate stiffness in a 
three-dimensional environment such as a porous tissue engineering scaffold is still an 
area that requires significant future investigation. 
5. Pore Size and Pore Size Distribution 
Pore size (Figure 2) is cell type specific (Murphy et al., 2010) and is arguably the most 
critical factor in the design of a tissue engineering scaffold optimised for a repair or 
regeneration of a specific tissue type. Pore size has a dramatic effect on cell seeding 
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efficiency within the scaffold (O’Brien et al., 2005) which can result in improved in vitro 
performance. If scaffold pore size is too small, cells are unable to rapidly infiltrate into 
the scaffold centre or homogenously populate the matrix. Densification of cells around 
the matrix periphery occurs, acting as a barrier to further cell infiltration and leading to 
avascular necrosis within the scaffold centre (Phelps 2010, Ko 2007).  Some investigators 
argue that having larger pores in the centre of an implant can help to support 
vascularisation of the implant when grafted onto a patient. It is believed that increased 
pore size with increasing depth is desirable (Mc Kegney et al., 2001). On the other hand, 
pores that are too big result in a significantly reduced specific surface area within the 
construct (Byrne et al., 2008).  
 
 
Fig. 2. SEM micrograph of a scaffold defining its pore structure. Wessels et al., 2008; S. Afr. j. 
sci. vol.104 no.11-12 Nov/Dec 2008 
Cells interact with the pore substrate via ligands, chemical binding sites naturally 
associated with extracellular materials such as collagen. The availability of these ligands 
for promoting cell binding is directly related to the specific surface area, which is 
related to mean pore size. Consequently, pore size must be sufficiently large to provide 
the ideal ligand density to allow binding of a critical proportion of cells to occur. While 
the mean pore size is critical, the distribution of pore size range around this mean also 
plays an important role. Given that pore size is cell type specific, tissue engineering 
scaffolds with heterogeneous pore size distribution provide an environment with 
heterogeneous optimisation of the structure. Local ligand densities will differ 
substantially throughout the matrix, as will the ability of cells to infiltrate and attach 
throughout the construct. Therefore, development of a homogenous structure with 
predictable cell adhesion, proliferation and differentiation characteristics requires a 
high degree of pore size homogeneity throughout and this is a characteristic offered by 
only a limited number of construct manufacturing processes. Figure 2 is an example of 
a porous structure of a collagen-based scaffold. An ideal scaffold is one which is open 
and has an interconnected pore network and a high degree of porosity (>90%), as it is 
easy for the scaffold to interact and integrate with the host (Freyman et al., 2001). 
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Clearly the optimisation of pore size is a critical design characteristic to allow 
optimisation, and consequently in vitro and in vivo performance, and the integration of 
cells within the developing extracellular matrix. 
6. Porosity, Pore Interconnectivity and Permeability 
Porosity is defined as the percentage of void space in a solid and its importance in 
tissue engineering scaffolds cannot be overstated. The degree of porosity in a scaffold 
with a given mean pore size will have a direct effect on the interconnectivity of the 
porous architecture and consequently the permeability/fluid mobility within the 
scaffold. These characteristics play an important role not only on the amount and rate of 
cell and fluid infiltration into the constructs but also facilitate the transport of nutrient 
and waste products throughout the cell-seeded construct, as well as construct 
vascularisation (Kuboki et al., 1998), for the duration of de novo tissue formation. These 
properties not only encourage complete tissue formation within the construct but also 
support the integration and mechanical interlocking of the implant. A scaffold which 
possesses an open and interconnected pore network, coupled with a high degree of 
porosity (>90 %) is ideal for cellular interaction and de novo tissue integration with the 
existing host tissue (Freyman et al., 2001). 
3. Scaffold biomaterials for orthopaedic tissue regeneration 
The first generation of biomaterials specifically designed for implantation into the human 
body appeared around the 1960s and 1970s. This first generation was characterised by 
attempting to “achieve a suitable combination of physical properties to match those of the 
replaced tissue with a minimal toxic response in the host” (Hench, 1980). These materials 
were designed primarily around the principal of bio-inertness i.e. the idea of causing as little 
disruption to the physiological environment while facilitating a primarily structural role. 
Fuelled by the initial success of many of these devices, the field rapidly began to focus on 
improving on the concept of bio-inertness and began to aspire to creating biomaterials that 
exhibited a degree of bioactivity i.e. to elicit a positive and controlled response within the 
implanted physiological macro-environment that would aid the healing or regenerative 
process. It was at this point that a large move towards the use of ceramic based materials 
occurred. 
3.1 Ceramics 
Ceramics (inorganic, non metallic materials) include the calcium phosphates, bioglasses and 
glass-ceramics (Hench, 1998). Bioceramics can be further classified as being osteoconductive 
(supporting bone growth) or osteoinductive (stimulating bone growth). While 
osteoconductivity is common to all types of bioceramics, relatively few are osteoinductive, a 
property that although extremely coveted, is not fully understood or easily replicated in 
synthetic materials (Barrere et al., 2008). The calcium phosphate based bioceramics, 
bioglasses and glass-ceramics are commonly used as scaffolds for bone tissue engineering as 
they have a compositional similarity to the mineral phase of bone (Hing et al., 2005). 
Hydroxyapatite (HA) and tri-calcium phosphate (TCP) are two of the most commonly used 
calcium phosphate bioceramics in tissue engineering applications. TCP is commonly used as 
the basis of biodegradable scaffolds due to its relatively rapid degradation rate (Ducheyne et 
al., 1993) and its osteoconductivity. HA, the mineral that occurs naturally in bone tissue, has 
also been used extensively as a tissue engineering scaffold material due to its 
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osteoinductivity. It is typically used for coating biomedical implants to induce bone 
regeneration, allowing the implant to integrate with the surrounding tissue. While HA was 
originally popular for use as a scaffold for tissue engineering, it is non-resorbable in bulk 
form which has limited its popularity as a bone graft substitute material (Figure 3). However, 
recent work on micro- and nano-sized particles has led to a paradigm shift regarding the 
degradability of this material and has re-ignited interest in this ceramic as a critical 
component of tissue engineering composite scaffolds optimised for bone tissue regeneration.  
Ceramic materials offer a facilitative environment to bone forming cells, offering mechanical 
support that promotes mineralisation in the hope of achieving stability equal to the normal 
anatomical tissue. Synthetic calcium phosphates have been popular for a number of 
different applications, ranging from a simple coating layer on prosthetic devices (Klein et al., 
1993) to being the implantable device itself, as porous bone graft substitutes in the repair or 
augmentation of bony defects. Many of these devices have been used clinically with some 
degree of success and are still widely used as bony void fillers. However, their clinical 
applications have been limited because of their brittleness and difficulty of shaping for 
implantation (Wang et al., 2003), low porosity and long term mechanical integrity issues 
(Bohner, 2010). Difficulties also exist in controlling the degradation rate of ceramics so as to 
ensure optimal resorption (Tancred et al., 1998).  Although HA is a primary constituent of 
bone and might seem ideal as a bone graft substitute, problems include a slow degradation 
rate (Marcacci et al., 2007), poor mechanical properties and new bone formed in a porous 
HA network cannot sustain the mechanical loading needed for remodelling (Wang et al. 
2003).  
3.2 Synthetic polymers 
Due to the numerous drawbacks of ceramic-based biomaterials, significant advances were 
made towards the development and use of bioresorbable second generation materials. These 
materials are polymeric-based and include many different biocompatible and bioresorbable 
materials, such as PLA and PGA scaffolds for use as implantable devices (Athanasiou et al., 
1998). Polymeric-based biomaterials have a number of advantages such as high mechanical 
strength and biodegradability. Their mechanical, physical and biological properties can be 
tailored to give a wide range of properties that are desirable for bone tissue regeneration. In 
addition, their degradation rates can be controlled, as can their degradation by-products 
(Hennick and Van Nostrum, 2002). Among the many biodegradable synthetic polymers 
used for tissue engineering applications, there are numerous reports on the use of polylactic 
acid (PLA), polyglycolic acid (PGA) and their copolymers poly (DLlactic- co-glycolic acid) 
(PLGA), which are approved by the US Food and Drug Administration (FDA). These 
polymers degrade by hydrolytic mechanisms and are commonly used because their 
degradation products can be removed from the body as carbon dioxide and water. 
Unfortunately, they are also associated with a number of problems, ranging from issues 
involving device rejection and resisting adequate resorption to promote vascularisation and 
ingrowth of new bone. Localised lowering of pH within the region of degradation can result 
in inflammatory responses. While these materials showed some promise, it is clearly evident 
from the lack of synthetic polymer-based products currently in use clinically as bone graft 
substitutes that synthetic polymers alone simply do not provide a sufficient degree of long-
term biocompatibility or performance required for the clinically-successful regeneration of 
bone tissue. 
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Fig. 3. Porous HA implant used to fill bony void but no resorption after 2.5 years (Cancedda 
et al., 2007) 
Polymeric materials however do offer a number of significant advantages over ceramics 
from a composite scaffold point of view. Biodegradable polymers can be used to encapsulate 
biologics and/or growth factors and can be designed to control the release kinetics of these 
substances via tailored polymer degradation properties for specific tissue regenerative 
applications. This ability presents a range of potentially controllable processes including cell 
growth, tissue regeneration and host response that can be influenced by developing suitable 
biopolymers (Hutmacher, 2000) for incorporation into novel composite materials. 
Appropriate selection and development of certain synthetic polymers for applications 
involving controlled biologic or growth factor release kinetics can be further advanced by 
the incorporation of ‘surface eroding polymers’, which biodegrade only at their surfaces. 
Poly(anhydrides), poly(orthoesthers) and polyphosphazene exhibit this property and offer 
numerous advantages over bulk degradation polymers (Rezwan et al., 2006). 
3.3 Natural polymers 
Natural polymers offer a number of significant advantages over synthetically-derived 
polymers due to their biocompatible, biodegradable and bioactive nature. By using 
materials that form the basic building blocks of organic systems, host response due to 
immunocompatibility issues can be drastically, and sometimes completely, reduced. This 
approach also ensures that these materials are easily biodegradable via the body’s own 
metabolic processes and that the resulting degradation by-products are non-toxic and can be 
easily assimilated or expelled from the tissue. Alternatively, natural polymers can usually be 
crosslinked using a number of means including physical or chemical crosslinking 
techniques. Physical crosslinking methods include UV radiation and dehydrothermal 
treatments, whilst cross-linking agents such as glutaraldehyde and carbodiimides (EDAC) 
can be used to produce chemically cross-linked natural polymers, allowing a customised 
degradation rate for different regenerative applications. This makes them ideal biomaterials 
for developing scaffolds with tailored biodegradation rates that can match the formation of 
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de novo tissue. Natural polymers used in bone tissue engineering include alginate, chitosan, 
fibrin, silk, glycosaminoglycans and collagen. Most natural polymers are biocompatible, 
degradable, and readily solubilised in physiological fluid (with exception of chitosan which 
is soluble under mild acidic conditions) (Seeherman and Wozney, 2005). This simple 
biomimetic approach means they can more closely mimic the natural extracellular matrix of 
tissues and can play a bioactive role in substrate cell interactions, such as promoting cell 
adhesion and proliferation. 
Alginate and chitosan are two natural polysaccharides that are not found within the human 
body but due to their structural similarity to the glycosaminoglycans (GAGs), they have 
been the focus of a significant body of scientific work evaluating their applications in 
regenerative medicine (Terada et al., 2005; Chenite et al., 2000). While these materials are 
attractive due to their low toxicity and biocompatibility, there are significant issues with a 
lack of load bearing ability (Suh and Matthew, 2000) which has limited their clinical 
applications as single phase materials but chitosan still plays a major role as a composite 
component, due to its flocculating and chelating properties (Zhang et al., 2010) and its role 
in composite mechanical stabilisation (Jiang et al., 2006). Structural proteins such as fibrin 
have also been used in tissue engineering applications.  Fibrin can be used as a natural 
wound healing material, and is most commonly used clinically as a sealant or adhesive. 
However, fibrin has very poor mechanical properties, degrades rapidly in vivo and cannot 
withstand physiological loading long-term when implanted into orthopaedic defects 
(Barrere et al., 2008). In spite of this, fibrin hydrogels have been used in muscle (Cummings 
et al., 2004) and cartilage tissue engineering (Hunter et al., 2004) in vitro. Silk has also been 
utilized as a tissue engineering scaffold for stem cell osteogenic differentiation of MSCs 
(Meinel et al., 2006). Silk as a biomaterial combines slow biodegradability, excellent 
mechanical properties, and biocompatibility Native silk fibers are some of the strongest 
natural fibers known, rival synthetic materials such as Kevlar in terms of tensile strength 
(Cuniff et al., 1994) and have been used as suture materials for over 20 years (Vepari and 
Kaplan, 2007). Silk scaffolds have previously been shown to support tissue engineering of 
bone in vitro (Altman et al., 2003). Glycosaminoglycans are found in the natural 
extracellular matrix of tissues i.e. skin, bone, and blood vessels and are a form of 
proteoglycan; organic polymers that are found in cells and that are a major component of 
the natural ECM. Given the importance of GAGs in stimulating normal tissue growth, the 
use of GAGs as components of a scaffold for tissue engineering appears to be a logical 
approach for scaffold development. Glycosaminoglycans (GAGs) are long, unbranched 
polysaccharides that do not elicit an immune response and have been used extensively for 
tissue engineering applications and can be copolymerized with collagen to increase the 
stiffness and toughness and decrease its degradation rate.  
Hyaluronic acid is one of the largest GAG components found in the natural extracellular 
matrix of all soft tissues and synovial fluid of joints (Drury and Mooney, 2003) and has been 
used in tissue engineering applications due to its role in structural organisation of the ECM 
components. However, its use has been limited due to rapid dissolution in water and fast 
biodegradation in biological environments. However, it can be chemically modified to 
produce a more hydrophobic molecule, thus reducing its solubility in water. Hyaluronic 
acid is a major component of cartilage matrix and is a viscoelastic material that forms 
random coils which entangle with each other at low concentrations and at high 
concentrations contains a very high viscosity dependant on shear stress making it pseudo-
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plastic. Chondrocytes in cartilage have a high affinity for Hyaluronic acid via CD44 
receptors and RHAMM (Lisignoli, 2001) and consequently it plays a more important role in 
cartilage tissue engineering constructs. 
Scaffolds fabricated from type I collagen and a glycosaminoglycan have been used to study 
cell migration and contraction in vitro (Sethi et al., 2002) as well as to induce regeneration 
of the skin, conjunctiva, and peripheral nerves in vivo (Harley et al., 2004; Yannas, 2001).  
Collagen as a scaffold material is ideal as it possesses all the biological prerequisite for 
successful implantation such as biocompatibility, immunogenicity, cell adhesion and 
proliferation (Murphy et al., 2010; Byrne et al., 2008; Berry et al., 2004; O’Brien et al., 2005). 
Collagen is the most abundant ECM protein in the human body and is readily isolated and 
purified from various animal species by enzyme treatment. Since collagen type I is the 
main organic component that in human bone tissue and it is the substrate on which bone 
mineralisation occurs during osteogenesis, collagen has been extensively used as the 
material of choice in nearly all commercial orthobiologic bone tissue engineering 
applications currently used clinically in the repair and regeneration of bone tissue. Two of 
the biggest advantages of using collagen-based scaffolds for tissue engineering applications 
are that (i) they provide an extremely attractive substrate for cell adhesion and 
proliferation and (ii) collagen scaffolds do not alter the phenotype of seeded cells. Another 
significant attribute is the recent FDA approval and clinical success of collagen-based 
scaffolds used for skin and nerve regeneration (Yannas, 2001). However, despite the 
excellent biocompatibility, collagen, like all other natural polymers, is insufficient 
mechanically for orthopaedic applications and this has limited its use in load-bearing bone 
tissue defects. 
4. Composite scaffolds for bone tissue regeneration 
4.1 Synthetic polymer and ceramic composites 
As a result of the problems associated with the use of single phase synthetic scaffolds, 
advances in the development and fabrication of composite scaffolds offered new materials 
using a combination of synthetic polymeric and ceramic phases. The development of these 
synthetically-based composites was believed to facilitate the development of biomaterials 
with all of the advantages of these single phase materials with none of their disadvantages. 
In spite of these efforts, these second generation bone graft substitutes have enjoyed limited 
clinical success (Ratcliffe, 2008) and simply do not possess all of the prerequisite 
characteristics of an ideal bone graft substitute (biocompatible, bioresorbable, 
osteoconductive, osteoinductive, structurally similar to bone, easy to use and cost-effective). 
The inability of synthetic materials to respond or adapt to changing physiological conditions 
means that they will always represent a compromise when used in the repair or 
regeneration of human tissue. As a result, this second generation of biomaterials have not 
been able to act as a viable clinical alternative to the gold standard, autogenous bone. 
Numerous innovative synthetic polymer-ceramic composites have been developed with 
porosities high enough to ensure cell infiltration and an environment potentially conducive 
to osteogenesis. While some have shown evidence of osteoinductivity when implanted into 
ectopic bone formation models (Barbieri et al., 2010), in in vitro conditions (Li et al 2010); 
and evidence of potent bioactivity (Deplaine et al., 2010), only a handful of these materials 
have been evaluated in large pre-clinical bone tissue defects. 
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4.2 Natural polymer and ceramic composites 
The combination of natural polymers with a reinforcing and bioactive ceramic phase has 
shown significant promise over the last decade with a number of these composites 
progressing to widespread clinical use (Lee and Goodman, 2009; Carter et al., 2009; Kitchel, 
2006; Muschler et al., 2005; Scabbia and Trombelli, 2004). While these materials fulfil many 
of the requirements of synthetic bone void fillers, none have shown conclusive clinical 
evidence of being a superior alternative to the clinical gold standard of autogenous bone. 
Such an ideal bone graft substitute must be capable of promoting rapid osteogenesis in vivo, 
encourage de novo bone formation and remodelling of the defect to restore anatomical 
normality and mechanical integrity, and biodegrade at the same rate as the progressing 
tissue regeneration process. Recent advances in composite biomaterials have led to a 
paradigm shift in this area towards the development and use of biomimetic composite 
scaffolds for orthopaedic regenerative medicine. Biomimicry, both in terms of composite 
composition and fabrication process may provide a compromise between the competing 
mechanical and the biological prerequisites needed to rapidly promote healing of bone 
tissue defects (Gleeson et al., 2010). The use of materials found naturally to occur within the 
human body allows the implantation of materials that are easily integrated, processed and 
degraded by the body. These materials form part of the normal “building blocks” of the 
human system and offer extremely favourable biological interactions. Advances in the 
processing and composite engineering of new composite materials comprised of these 
naturally-occurring materials offer exciting possibilities for not only meeting a compromise 
between the mechanical and biological prerequisites for implantation and bioactivity, but 
also for directing and controlling the chemical, biological and mechanical events that occur 
during the regenerative process.  
There are a large number of natural materials currently used as the components of 
composite scaffolds for orthopaedic regenerative medicine. While there are many different 
materials used to promote bone tissue repair, bone’s native composition of predominantly 
type I collagen and hydroxyapatite makes these materials an obvious choice as the basis for 
a composite biomaterial capable of supporting and promoting the bone regenerative process 
(Dawson et al. 2008). Recent studies have shown that the interaction between osteoblasts 
and PLLA scaffolds can be improved by the application of a collagen-HA coating (Jiashen et 
al., 2010) clearly demonstrating the potential of a composite material composed of only 
collagen and hydroxyapatite for use as a bioactive bone graft. These composite scaffolds 
were traditionally fabricated using a number of different techniques involving some form of 
pre-processing step, with the scaffold architecture subsequently formed via a number of 
distinct processes, all of which possess numerous advantages and disadvantages 
(particulate leaching methods, phase separation, lyophilisation, foaming, emulsion 
templating, and solid free form (SFF) fabrication).  
Current advances in composite fabrication have been driven by the desire to replicate the 
hierarchical scale of the naturally-occurring tissues. Bone is composed of mineralised 
tropocollagen molecules, arranged in a distinct quarter stagger arrangement, with 
nanometre-sized hydroxyapatite crystal intimately associated with these fibrils. The nature 
of these nanohydroxyapatite particles endows them with a number of distinct regenerative 
advantages relative to the micron-sized particles and this has been a driving factor in the 
move towards the hypothesis that biomimetic scaffolds fabricated using biomimetic 
processes may allow the development of composite scaffolds optimised to promote rapid 
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osteogenesis in vivo. As a result, many recent studies have utilised biocompatible or 
bioactive dispersants, such as chitosan (Zhang et al., 2010b) or biomimetic fabrication 
methods for the in situ mineralisation of collagen-HA scaffolds during the fabrication 
process (Zhang et al., 2010a; Xu et al., 2010; Yoshida et al.,2010; Kikuchi et al., 2004).  
One of the earliest attempts to combine biologically-occurring composite constituents with 
biomimetic fabrication processes to form a bone graft substitute material was carried out by 
Kikuchi (Kikuchi et al., 2004). This approach involved a self-organisation mechanism 
designed to synthesis a bone-like collagen/hydroxyapatite nanocomposite material for use 
as a bone tissue engineering scaffold. There are many motivating factors that support the 
use of nano HA, most critically increased in vivo resorption rate, increased osteoblast 
adhesion and proliferation and increased bone formation in vivo. By using a self-
organisation mechanism that involves the in situ mineralisation of a collagen solution, 
Kikuchi and colleagues were able to develop a collagen/HA composite that exhibited bone-
like orientation of nano-sized hydroxyapatite crystals, aligned along the length of the 
collagen fibrils. However, although in vitro and preliminary in vivo data were promising, 
their application to orthopaedic regenerative medicine remains to be elucidated. In addition, 
control and regulation of this process and the resulting nature of the fabricated HA can be 
difficult with implications on the purity and crystallinity of the resulting mineral phase. 
Given that HA crystallinity and purity plays a significant role in promoting bone tissue 
formation in vivo (Zhang et al., 2010a; ter Brugge et al., 2002), the ability to produce pure 
collagen-HA scaffolds of high purity and crystallinity is desirable from a tissue engineering 
perspective. 
However, a significant flaw that exists in the biomimetic fabrication approach is the 
assumption that an ideal optimised bone graft substitute material must mimic the 
composition and structure of the final bone tissue. This postulation does not consider that a 
truly biomimetic composite scaffold for orthopaedic regenerative therapies must match the 
idealised environment that supports the earliest stages of osteogenesis. This presents the 
biggest current challenge within the field of composite scaffolds for orthopaedic 
regenerative medicine, namely to develop a composite material that meets the multitude of 
prerequisite characteristics necessary to induce, promote and support the process of 
osteogenesis. Such a composite scaffold must (i) be highly porous to facilitate rapid and 
complete cellular infiltration once implanted (ii) provide surfaces and an environment that 
encourages cellular adhesion and proliferation (iii) be highly permeable to facilitate the 
exchange of nutrients and waste products throughout the scaffolds and preventing 
avascular necrosis (iv) be sufficiently strong to withstand surgical manipulation and the 
implantation procedure (v) exhibit a high degree of pore interconnectivity (vi) must be 
osteoconductive and ideally osteoinductive (vii) biodegradable, biocompatible and bioactive 
and (viii) possess an optimised pore size and pore size distribution to facilitate homogenous 
mineralisation of the composite scaffold in vitro and in vivo. 
Many of the tradition methods for fabricating scaffolds for tissue engineering are not ideal 
for the development of highly biocompatible scaffolds with the prerequisite pore network, 
porosity and pore interconnectivity characteristics that are increasingly being recognised as 
determining factors in the long-term in vivo viability of tissue engineering construct. 
Problems associated with these techniques include, but are not limited to, poor control over 
internal architecture and a limited range of pore sizes, residual solvent and residual 
porogens, porosity limits of about 70% and highly heterogeneous nature of the pore 
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structure, limitations the development of photopolymerisable and biocompatible, 
biodegradable liquid polymer materials, high processing temperatures, use of toxic organic 
solvents and lack of mechanical strength. In addition, one of the major barriers to the 
successful development of a collagen-HA scaffold using these techniques is the difficulty in 
achieving a homogenous distribution of the HA throughout polymer-based matrices 
(Supova, 2009), an issue that can have a significant effect on a collagen-HA biomaterial’s in 
vivo vascularisation and production of newly formed bone tissue (Lyons et al., (2010); Zhang 
et al. (2010a)). Recent attempts to overcome this issue have employed additional naturally-
derived dispersants in an attempt to achieve a homogenous dispersion of the osteoinductive 
HA particles throughout the fabricated matrix (Zhang et al., 2010b) but radiological results 
do not provide evidence of the ability of these scaffolds to heal critically-sized bone defects. 
Freeze-drying is a process which can potentially solve many of these composite scaffold 
fabrication issues and is ideally suited to organic biomaterials such as collagen. This 
technology has a number of distinct advantages with regard to the production of high 
porosity, highly interconnected, homogenous biological constructs. Currently, our Tissue 
Engineering Laboratory produces a range of highly porous collagen-based scaffolds, 
using a constant cooling lyophilisation process, with specific applications including bone 
and cartilage tissue repair (Murphy et al., 2010, Farrell et al., 2009). These scaffolds have 
been optimised for bone tissue healing and have recently been shown to provide ideal 
substrates for supporting the process of osteo- and chondro-genesis in vitro (Farrell et al., 
2006). Our laboratory’s approach has involved the optimisation of these collagen-based 
scaffolds in terms of composition (Tierney et al., 2009), cross linking density (Haugh et al., 
2009) and pore architecture (Murphy et al., 2010) for use in bone tissue engineering 
applications. 
Case study: Highly porous collagen hydroxyapatite scaffolds for bone tissue repair 
We have recently developed the ability to combine our highly porous, optimised collagen 
scaffolds with an osteoinductive HA phase in an effort to improve their osteogenic potential 
and provide the prerequisite mechanical integrity to promote rapid in situ bone tissue 
regeneration (Gleeson et al., 2010) (Figure 4). By combining the two primary constituents of 
human bone tissue, namely type 1 collagen and high purity, highly crystalline 
hydroxyapatite particles using a novel mixing process (WO200896334A2), a highly porous 
composite tissue engineering scaffold with a high degree of pore interconnectivity, 
improved mechanical strength, permeability and cellular bioactivity was developed, 
overcoming traditional HA dispersion problems and exhibiting a homogenous distribution 
of the osteoinductive HA phase. The combination of the extremely biocompatible and 
biodegradable collagen scaffold with an osteoinductive mineral component (Barrere et al., 
2003) provides an ideal mechanical and biological environment to facilitate cell recruitment 
and maintain pore structure in order to promote healing.  
By optimising these compliant and highly porous collagen-hydroxyapatite scaffolds to 
promote mineralisation upon implantation (Hutmacher et al., 2000), these materials have the 
potential to rapidly produce de novo bone tissue with a load bearing capacity within the 
newly mineralised bone tissue graft. These scaffolds possess all the ideal prerequisite 
characteristics of a biodegradable scaffold optimised for bone tissue regeneration, are 
comprised only of bone’s natural constituent materials, and have demonstrate their ability 
to promote osteogenesis in vitro and in vivo repair of critical-sized bone defects (Figure 4). 
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These highly porous collagen hydroxyapatite scaffolds have also been used pre-clinically in 
the repair of critical-sized segmental bone defects in long bones and show a rapid return to 
anatomical normality (as evident by formation of a continuous marrow cavity through the 
regenerated segmental defect), as well as evidence of de novo tissue remodelling and rapid 
restoration of load bearing ability after only 6 weeks implantation (unpublished data). These 
materials appear to demonstrate real potential as a bone graft substitute materials, capable 
of facilitating and promoting osteogenesis in vivo.  
 
 
Fig. 4. MicroCT slice of representative level of mineralisation within rat calvarial defect 
centre showing defect boundary edges in (a) empty defect group, (b) collagen HA scaffold 
group after 28 days implantation. Almost complete defect bridging was observed in the 
collagen HA group, with mineralisation level comparable to surrounding native calvarial 
bone tissue (Gleeson et al., 2009) 
5. Scaffold biomaterials for osteochondral tissue regeneration 
Articular cartilage is a highly specialised tissue found covering the surfaces of the bony ends 
of all synovial joints in the human body. Its function is to lubricate joint movement and 
absorb small shock impacts within a joint. Articular cartilage is primarily composed of 70-
80% water, 15% collagens (80% of which is type II collagen) and 5% cells. In synovial joints, 
the overlying lubricating articular cartilage is attached to the bone via a specialised tissue 
unit, known as osteochondral tissue. The structure and composition of osteochondral tissue 
is made up of a number of distinct but seamlessly integrated layers which vary in 
composition and structure according to their function and this serves to transfer mechanical 
forces at articulating surface down to the stiffer underlying subchondral bone via an 
intermediate tidemark layer, known as articular calcified cartilage. Cartilage is significantly 
different to bone from a regenerative point of view as it has a low regenerative capacity and 
damage to this tissue is irreparable and almost inevitably leads to the development of 
osteoarthritis (OA) within a joint and the eventual replacement (Arthroplasty) of the 
affected joint. Traditionally, the inherent lack of a natural regenerative capacity meant that 
autografting, allografting and joint replacement therapies offered the best potential 
outcomes for patients but recent advances in composite scaffolds are offering new 
regenerative possibilities. 
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Tissue engineering via in situ tissue regeneration may provide the prospect of regenerating 
cartilage and osteochondral tissue using a combination of an optimised tissue engineering 
scaffold and a source of potent progenitor cells used because of their ability to differentiate 
into a specific cell type and provide a source of extracellular matrix. This approach to 
cartilage and osteochondral repair is based on creating access to the most abundant source 
of nearby progenitor cells which reside in the underlying bone marrow. It is believed that 
this multi-tissue approach has the potential to offer improved restoration of the entire 
osteochondral unit and may potentially be more successful than simply trying to regenerate 
the avascular and largely non-regenerative mature articular cartilage tissue alone. 
There are a number of critical factors that must be taken into consideration when designing 
tissue engineering scaffolds optimised for osteochondral repair via in situ tissue 
regeneration (Frenkel and Caesare, 2003). An ideal osteochondral graft substitute must (i) be 
biocompatible, (ii) provide adequate mechanical properties to withstand the implantation 
procedure and the subsequent mechanical and hydrodynamic loading within the joint, (iii) 
possess sufficiently high levels of porosity to allow ingrowth of host tissue and/or seeded 
cells, (iv) be retained at the site of implantation (Beris, 2005), (v) support and direct 
regeneration of the two predominant tissue types, namely bone and cartilage (Hutmacher, 
2000) to ensure overlying repair cartilage is adequately supported, (vi) be optimised for cell 
attachment to favour colonisation by native cells (Coutts et al., 2001), (vii) promote 
integration with the existing tissues (Beris, 2005). 
Composition is elementary in creating biologically active materials that can induce synthesis 
of new tissue in vitro and in vivo. As with bone graft substitutes, there exists a wide array of 
materials that have been used in an attempt to produce an optimised osteochondral graft 
substitute. Synthetic polymers have been widely used for tissue engineering. Polymers such 
as polylactide (PLA), polyglycolide (PGA) and their copolymers (poly(D,L-lactide-co-
glycolide) are commonly used due to their degradability and US Food and Drug 
Administration (FDA) approval for clinical use. They have been investigated as scaffolds for 
cartilage tissue engineering since the early 1990s (Vacanti et al., 1991) and have formed 
cartilage-like tissue with good mechanical properties (Ma and Langer, 1999). The major 
advantages of the synthetic polymers include a wide range of tailored structural properties 
and the lack of disease transmission. PLA scaffolds have shown some promise in vivo but 
de novo tissue was found to be biochemically inferior to native cartilage tissue (Dounchis et 
al., 2000). PLA and PLA co-polymer composites have also been investigated for use in 
cartilage tissue repair (Niederauer et al., 2000) and shown evidence of hyaline cartilage and 
good bony restoration. However, there are many disadvantages with these materials, 
predominantly associated with the biological interactions that take place between the host 
and these synthetic materials over time and ultimately the translation of these synthetic 
polymer-based constructs into human clinical applications has not been seen due to 
concerns about their ability to illicit foreign body host responses and concerns of localized 
and systemic effects due to their toxic degradation by-products in vivo (Stoop, 2008)  
Scaffolds developed using components of the ECM are generally more favourable than 
artificial polymers due to their ability to regulate cell function through specific cell-matrix 
interactions through ligand-integrin associations. Fibrin has been used extensively in the 
development of tissue engineered constructs for cartilage tissue engineering but the 
biochemical and morphologic features were not consistent with those of normal articular 
cartilage and exogenous fibrin may trigger an immune response (Kawabe and Yoshinao, 
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1991). Currently the use of fibrin is primarily limited clinically to securing perichondrial 
scaffold grafts. Agarose is another material that has been used for cartilage repair but does 
not resorb well and has been shown to elicit a foreign body giant cell response in vivo 
(Rahfoth et al., 1998). Alginate as a matrix for supporting chondrogenesis show improved 
biological performance seen histologically but resulting repair has been shown to be 
biochemically distinct form native tissue (Dausse et al., 2003).  
Collagens and polysaccharides are the most commonly used components of the ECM in 
Tissue Engineering (TE). The ability of these materials to be fabricated into highly porous 
scaffolds allows enhanced diffusion of culture medium as well as an even distribution of 
ligands present for cell association and cellular migration (Murphy et al., 2010). The use of 
natural materials in TE reduces the risk of having products of wear and degradation that 
may elicit host tissue immune response. Collagen is commonly used in TE due to its 
abundance and ubiquitous nature which allows cellular biocompatibility. From a 
biomimetic point of view, osteochondral graft substitutes based on collagen and 
proteoglycans may facilitate the development of natural substrates capable of directing and 
regulating the chondrogenic process. Collagen-based matrices have been shown in a 
number of studies to be capable of maintaining a differentiated phenotype of chondrocytes 
and promoting appropriate proteoglycan synthesis in vitro (Wakitani et al., 1994). In 
combination with seeded chondrocytes and a standard microfracture technique, collagen-
based scaffolds have been shown to be capable of regenerating hyaline-like cartilage tissue 
in an ovine model (Dorotka et al., 2004). This has also been seen in rabbit model where 
chondrocytes in collagen fibers induced a hyaline-like repair that was biochemically and 
mechanically similar to native tissue after 6 months (Frenkel et al., 1997) but hyaline-like 
tissue formation has long been accepted as only a temporary solution (Buckwalter and 
Mankin, 1998). In addition, integration with the existing host tissue in studies using single 
phase collagen type I scaffolds has been notably disappointing (Wakitani et al., 1998; Frenkel 
et al., 1997)  Alternatively, collagen type II, a primary component in native articular 
cartilage, has been shown to promote a more chondrocytic phenotype when used as an in 
vitro substrate for chondrogenesis results in increase DNA and GAG content, compared to 
collagen type I-based scaffolds when seeded with chondrocytes while type I matrices show 
a more fibroblastic phenotype (Nehrer et al., 1997). Type II collagen has also been shown to 
provide chondroinductive signalling resulting in chondrogenic differentiation of adipose 
tissue-derived stem cells (Lu et al., 2010) and when combine with type I collagen and GAG, 
these scaffolds have outperformed ACI repair in pre-clinical trials (Breinan et al., 2001) 
Hyaluronic acid (HyA), abundant in the synovial fluid and ECM, plays an important role in 
structural organisation of the ECM components, maintenance of ECM space, transport of 
ions and nutrients, and maintenance of tissue hydrodynamics. Studies have shown that 
HyA addition in collagen scaffolds has resulted in a change of the matrix stiffness, 
fibrillogenesis and matrix viscoelasticity (Tang et al., 2007). Hence, the addition of HyA in 
collagen scaffolds initiates biophysical cues that influence cell response. The properties and 
roles of hyaluronic acid are however dependant on its molecular weight. Low molecular 
weight hyaluronic acid has been shown to induce angiogenesis whereas high molecular 
weight hyaluronic acid is more chondroinductive in vivo (Loken et al., 2008). A number of 
commercial scaffolds are currently available and are based predominantly on Hyaluronic 
acid and have shown very positive short term results. Hyalograft C (Fidia Advanced 
Biomaterials) is a 3-dimensional engineered scaffold made of Hyaff 11, the benzyl ester of 
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hyaluronic acid and has been used in clinical studies and has resulted in over 95% of 
patients returning with normal or nearly normal cartilage after arthroscopic examination 
after 4 years with another study showing no statistical significant between patients receiving 
ACI and Hyalograft C (Grigolo et al., 2005).  Hyaluronic acid has been used in combination 
with Chondroitin sulphate and gelatin, forming tri-copolymer scaffolds and used to 
investigate in vitro chondrogenesis using porcine chondrocytes. These scaffold show 
excellent results, with even distribution of chondrocytes, evidence of newly secreted ECM 
and collagen type II, and good phenotype retention for up to 5 weeks (Chang et al., 2003). 
While many of these materials possess the basic requirements of biocompatibility and can be 
manipulated so as to provide adequate mechanical support, porosity, cell attachment and 
retention at the site of implantation, the regeneration of osteochondral tissue requires a 
multiplicity of biological and biochemical functions that are difficult to provide when using 
only a single phase material. Indeed, the possibility of a single phase scaffold promoting 
both chondro- and osteo-genesis and replicating the natural anatomical structure of native 
osteochondral tissue seems highly problematic (Niederauer et al., 2000). Native 
osteochondral tissue exhibits a multi-phase anatomical structure, comprised of multiple 
layers seamlessly interwoven and integrated on a molecular level. Given this more 
multiphase anatomical structure, it would seem clear that a more advanced biomimetic 
strategy may be required to comprehensively regenerate the tissue and ensure long-term 
repair of a defect. This has been recognised within the field and more and more we are 
seeing the emergence of multi-layered scaffolds, attempting to regenerate multiple tissue 
types in vivo. The use of bi-layered scaffolds allows the development of optimised, tissue-
specific biological environments within each respective layer via variations in mechanical, 
structural, and chemical properties (O’Shea et al., 2008). These scaffolds can be designed to 
better mimic the native ECM for each tissue type independently rather than trying to 
fabricate a construct that attempts to compensate for the functional requirements of both 
cartilage and bone in a single structure but fail to address the mechanical and biological 
need for an intermediate calcified cartilage phase to comprehensively integrate these distinct 
tissue types in vivo.  
A number of recent studies provide convincing evidence supporting the need for a scaffold 
comprised of a number of distinct constituents, contained within a gradient scaffold 
architecture. Gradient scaffold pore architectures have been used to investigate the effect of 
a gradient structure on in vitro chondrogenesis (Woodfield et al., 2005). In vitro culture on 
these scaffolds can lead to zonal distributions of glycosaminoglycans (GAGs) and collagen 
type II while changes in the permeability or fluid mobility of scaffolds (that would occur 
within scaffolds with varying pore size gradients) have also been shown to preferentially 
favour chondrogenic differentiation of BMSCs and cartilaginous ECM production of 
chondrocytes (Kemppainen and Hollister, 2010). Computational models of osteochondral 
repair (Kelly et al., 2006) using a mechano-regulation algorithm point to the importance of a 
depth-dependent mechanical properties and permeability as optimum for osteochondral 
repair. The use of bi-layered scaffolds was first pioneered by Shaefer and colleagues 
(Schaefer et al., 2002) and provided promising results as the first attempt at using multi-
phase scaffolds to regenerate osteochondral defects in rabbit knees. The results showed 
good integration with the underlying bone but not with the peripheral cartilage, although 
the constructs did show evidence of engineered cartilage that remodelled into osteochondral 
tissue. Subsequent studies applying this biomimetic approach have resulted in distinct 
www.intechopen.com
Composite Scaffolds for Orthopaedic Regenerative Medicine 
 
49 
tissue healing within respective layers of a bi-layered construct (Tampieri et al., 2008) with 
evidence of a mineralised interface (Schek et al., 2004). 
Although multi-layered scaffolds can be fabricated by the combination of individually 
fabricated layers, standard techniques for combining these layers (such as suturing and 
gluing) are problematic from both a mechanical and a biological point of view. Currently, 
bi-layered scaffolds with a seamlessly integrated structure are only available composed of 
synthetic materials (Ghosh et al., 2008) with one exception (Chondromimetic, Tigenix) and 
although these multi-layered constructs have shown promise in vitro, a significant 
amount of in vivo data needs to be gathered regarding their clinical efficacy (O’Shea et al., 
2008). Consequently, the ability to fabricate multi-layer natural scaffolds exhibiting layer-
specific composition, porosity, pore size, mechanical properties, degradation rate and 
permeability as part of a seamlessly integrated construct is of significant interest. Our 
laboratory has recently developed a novel multi-layered natural scaffold for 
osteochondral tissue repair, developed using our existing collagen-based technologies 
previously used as novel bone graft substitutes. These novel multi-layered scaffolds for 
use as osteochondral graft substitutes are designed to promote regeneration that 
replicates the structure and composition of healthy anatomical osteochondral tissue. 
These scaffolds exhibit a seamless integration between the distinct layers, ensuring rapid 
cellular infiltration, creation of optimised, tissue-specific biological environments in each 
respective layer via variations in mechanical, structural, and chemical properties and are 
designed to better mimic the native ECM of each tissue type independently. These 
scaffolds may provide a characteristic interfacial region that may help to inhibit the 
phenomenon of growth factor–induced angiogenesis and the consequential up growth of 
osseous tissue into the cartilage region. In addition, the use of collagen as a basic 
component in all three layers provides the opportunity to load distinct bioactive 
molecules within each distinct scaffold layer. 
Case study: Multilayer composite scaffolds for osteochondral tissue regeneration  
Our laboratory’s approach has been the development of a number of novel lyophilisation 
fabrication techniques that facilitate a large degree of control over the manufacture of each 
layer, while still resulting in a completely integrated construct, free from interfacial barriers 
to cell infiltration and migration. This multi-layered polyphasic scaffold exhibits a structure 
and composition designed to replicate the environments of the three major layers of 
anatomical osteochondral tissue, namely subchondral bone, calcified cartilage and cartilage. 
This material is currently being optimised to provide a substrate for high quality hyaline 
cartilage repair tissue, seamlessly integrated with a supporting calcified cartilage and bone 
layers. Each of the three layers possesses a unique composition. The top or cartilage layer 
contains type I collagen, type II collagen and glycosaminoglycan. Glycosaminoglycans can 
easily be cross-linked to collagen and the level of cross-linking can alter the mechanical 
properties of these scaffolds as well as improving their degradation rate (Lee et al., 2001). 
Chondroitin sulphate (CS) is the most abundant type of GAG in the natural cartilage tissue 
and is fundamental in the maintaining the structure of cartilage tissue as well as generating 
electrostatic repulsion via highly charged sulphate groups in the structure. CS manipulates 
chondrocyte morphology, proliferation and proteoglycan production due to the GAG 
molecules acting as ligands for the regulation of metabolism and gene expression in 
chondrocytes. This biochemical is widely used both in vitro and in vivo due to its anti-
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inflammatory activity as well as the decrease in catabolic activity of proteolytic enzymes 
such as Nitric Oxide which degenerate cartilage matrix (van Susante et al., 2001). Ko and 
colleagues (Ko et al., 2009) investigated the effect of collagen-chondroitin sulphate-
hyaluronan (CCH) composites on chondrogenesis and their results demonstrated that CCH 
scaffolds showed upregulated cartilage specific gene expression of collagen-2 and aggrecan 
compared to scaffolds with no GAGs. Furthermore their results revealed that the CCH 
scaffolds provided the best microenvironment for the preservation of chondrocyte 
phenotype.  
The intermediate or calcified cartilage layer contains type I collagen, type II collagen and 
hydroxyapatite while the bottom or bone layer is identical in composition to our optimised 
bone graft substitute material (Gleeson et al., 2010), specifically type I collagen and 
hydroxyapatite. We have shown previously that the inclusion of the osteoinductive 
hydroxyapatite phase in discrete amounts within the collagen-based scaffolds allows a 
degree of control on the osteogenic process in vitro. The composition of the intermediate 
layer is designed to act as an interface between the cartilage and bone layers while at the 
same time facilitating a degree of integration between the tissues engineered within each 
layer. The fabrication process produces a seamlessly integrated construct. Mechanical 
testing of the interfacial strength has shown excellent interfacial bonding, with no 
delamination occurring at scaffold yield and evidence of collagen fibre pullout at the yield 
point. Interestingly, failure of these construct in tension does not occur at the interface but 
within the mechanically weakest layer, strong evidence of the seamless integration at the 
layer interfaces. 
We have shown that the addition of the GAGs to the top cartilage layer appears to increase 
the levels of cartilage ECM specific sulphated GAG production when these constructs are 
cultured for up to 28 days in vitro. In addition, the type of GAG added to the top layer of the 
multi-layered construct has a dramatic effect on cellular infiltration, specifically the addition 
of hyaluronic acid significantly improves cell distribution throughout the constructs when 
seeded with MSCs and cultured in chondrogenic media (Matsiko et al., 2010). We have also 
shown that the addition of type II collagen results in increased production of sulphated 
GAG assessed using Safrinin-O staining within the constructs after culture with rat MSCs in 
chondrogenic media for up to 28 days (Levingstone et al., 2010). These constructs have also 
been investigated using a preliminary in vivo pre-clinical rabbit osteochondral defect model 
in a small cohort of animals (n=2). This work was carried out with ethical approval from the 
RCSI research ethics committee. A critical-size osteochondral defect (3 mm diameter, 4 mm 
deep) was created in the femoral condyle of 2 New Zealand White Rabbits. The multi-
layered scaffold was cut to size and placed into the osteochondral defect with no fixatives 
and following the procedure the rabbits were allowed to weight bear with appropriate 
analgesia. 12 week healing compared to empty defects can be seen in the MicroCT images in 
Figure 5.  
The femoral condyles are currently being assessed histologically to investigate the level of 
healing and composition of the regenerated tissue. Although MicroCT does not allow a 
detailed analysis of the overlying chondral repair tissue in these samples, it is clear that a 
significant amount of subchondral bone healing has taken place and that the defect has been 
completely sealed at the condylar surface. Additional images taken of the defect surface 
after 12 weeks (Figure 5) show evidence of integration between the in situ regenerated tissue 
within the defect and the peripheral hyaline cartilage and the macroscopic appearance of 
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this tissue closely matches the surrounding cartilage in terms of colour and glistening 
appearance. 
 
 
 
   
Fig. 5. (a) MicroCT slice of empty control (Left) and scaffold-treated group (Right) after 12 
weeks implantation. Note the extensive subchondral remodeling and appearance of 
cartilage-like repair tissue at joint surface (b) Appearance of treated condyle after 12 weeks 
implantation. Good repair tissue integration with surrounding cartilage and hyaline-like 
appearance of de novo tissue 
While there remains much work left to do on these constructs and indeed within the field of 
multi-layered constructs for osteochondral tissue repair, preliminary in vitro and in vivo 
studies have been extremely promising. The natural composition of the structure, in 
combination with the layer specific control of composition, structure and mechanical 
properties endow these materials with great potential for facilitating the in situ repair of 
osteochondral tissue and may finally offer a clinical therapy that may finally offer patients a 
real regenerative possibility for damaged or degenerated osteochondral tissue. 
6. Conclusions and future directions 
The regenerative capabilities of mature bone and osteochondral tissue differ significantly 
and this has resulted in the two distinct approaches, summarised in this chapter, in an 
attempt to repair or regenerate these tissues either in the lab or within the patient 
themselves. Interestingly, despite their final differences, the genesis of these tissues begins 
in a common cartilaginous anlage present during limb development. The future of bone and 
osteochondral tissue repair may therefore lie in our understanding of the process of 
endochondral ossification, and an ability to control and direct this process using improved 
advances in composite materials and technology. Angiogenesis plays a critical role in 
a
b
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endochondral ossification, during which the avascular cartilaginous tissue precursor is 
gradually transformed into vascular osseous tissue by the migration of blood vessels via 
cartilage channels. This ingrowth and advancement of vasculature provides the first set of 
cells capable of disintegrating the cartilage ECM, preventing avascular necrosis and 
supporting osteogenesis and subsequent bone development and growth. The ability to 
direct or control tissue vasculogenesis using cutting-edge composite materials and scaffolds 
may lead to new ways to develop both de novo bone and osteochondral tissue, possibly 
from a common composite scaffold.  
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